Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

297 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-18

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of a Mobile Geriatric Team With a Pharmacist on the Optimisation of Prescriptions in Elderly Inpatients

NCT04151797

Medication Therapy Management

COMPLETED NA

Therapeutic Optimization in Patients in Acute Geriatric Care at University Hospital of Montpellier

NCT04223921

Geriatrics Clinical Pharmacy

UNKNOWN

Adverse Drug Event Prevention Using Structured Pharmacist Review

NCT01467128

Adverse Drug Reactions

COMPLETED PHASE4

Effect of Systematic Medication Review in Elderly Patients Admitted to an Orthopedic Department

NCT00738816

Elderly

COMPLETED NA

A Collaborative Approach to Medication Reviews for Older Patients With Polypharmacy

NCT03909035

Medication Therapy Management

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Group Type NO_INTERVENTION

No interventions assigned to this group

B1 interventional group

Group Type EXPERIMENTAL

Mutlidisciplinary medication Review (MMR)

Intervention Type OTHER

The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted

B2 interventional group

Group Type EXPERIMENTAL

Mutlidisciplinary medication Review (MMR)

Intervention Type OTHER

The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted

Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up

Intervention Type OTHER

Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.

Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.

Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mutlidisciplinary medication Review (MMR)

The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted

Intervention Type OTHER

Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up

Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient.

Community follow-up A summary of the follow-up report stating the therapeutic modifications (called below multidisciplinary correspondence documents) will be sent to the community pharmacist and physician. Within 2 months of discharge, the pharmacist performs a follow-up of medication changes accepted and not accepted by the community physician.

Three months after discharge, the patient's community pharmacist will be contacted to assess whether the changes proposed in the MMR were accepted.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The patient (or their representative) has given his consent and signed the consent form.
* The patient is affiliated to a health insurance programme.
* The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
* The patient is available for a follow-up of 3 months.
* The patient is hospitalized in the surgery department.
* Patient with a Trivalle score greater than or equal to 2 (≥).
* Patient living in a nursing home or going back home after hospitalization.

Exclusion Criteria

* The subject is participating in another category I interventional study.
* The subject is in an exclusion period determined by another study.
* The subject is under safeguard of justice.
* It is not possible to give the patient (or his/her trusted-person) informed information.
* Palliative care

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No